预防性使用依托考昔预防乳腺癌患者紫杉烷相关急性疼痛综合征:一项II期随机试验
该II期随机试验纳入144例接受四周期多西他赛化疗的乳腺癌患者,按1:1随机接受预防性依托考昔(60 mg,第1天至第8天)或无预防性治疗。依托考昔组T-APS总体发生率57.1%,对照组91.5%(P<0.001);重度T-APS发生率分别为11.4%和54.9%(P<0.001)。结论认为预防性使用依托考昔可显著降低多西他赛所致急性疼痛综合征的发生率和严重程度,并可能减少多西他赛所致周围神经病变。
要点
- 依托考昔组T-APS总体发生率为57.1%,对照组为91.5%(P<0.001)。
- 依托考昔组重度T-APS发生率为11.4%,对照组为54.9%(P<0.001)。
- 依托考昔组FACT-B平均评分(103.79-107.24)显著高于对照组(93.88-96.71)。
核心结论
- 预防性使用依托考昔可显著降低多西他赛所致急性疼痛综合征的发生率和严重程度,并可能减少多西他赛所致周围神经病变。
研究设计与样本
- II期随机试验,纳入144例接受四周期多西他赛为基础化疗的乳腺癌患者,按1:1随机分为预防性依托考昔组(60 mg,第1天至第8天)和无预防性治疗对照组。
- 主要终点为所有周期T-APS的总体发生率;次要终点包括重度疼痛(0-10分量表评分大于5)发生率、T-APS严重程度和持续时间、FACT-B子量表、慢性感觉和运动神经毒性及不良事件。
主要发现
- 所有化疗周期中,依托考昔组T-APS总体发生率为57.1%,对照组为91.5%(P<0.001)。
- 依托考昔组和对照组重度T-APS发生率分别为11.4%和54.9%(P<0.001)。
- 依托考昔组FACT-B平均评分(103.79-107.24)显著高于对照组(93.88-96.71)(第1周期P=0.001,第2-4周期P<0.001)。
- 四周期多西他赛化疗后,依托考昔组FACT-Neurotoxicity子量表平均评分显著高于对照组(38.46,95%CI:37.63-39.29 vs 34.59,95%CI:33.73-35.45;P<0.001)。
- 肌电图显示,依托考昔组大多数外周感觉神经的动作电位波幅和传导速度较对照组显著改善。
关键数值与推荐
- 依托考昔预防性给药方案为60 mg,第1天至第8天。
- 重度疼痛定义为0-10分量表评分大于5。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For patients with breast cancer who receive docetaxel chemotherapy, taxane-associated acute pain syndrome (T-APS), considered a form of neural pathology, is a significant clinical problem. We evaluated the effect of prophylactic etoricoxib on T-APS in patients with breast cancer. MATERIALS AND METHODS: We conducted a phase II randomised trial including 144 patients with breast cancer receiving four cycles of docetaxel-based chemotherapy. Patients were randomised in the ratio 1:1 to receive prophylactic etoricoxib (60 mg, Day 1 to Day 8) or no prophylactic treatment. The primary end-point was the overall incidence of T-APS across all cycles. Secondary end-points included the incidence of severe pain (greater than 5 on a scale 0-10); severity and duration of T-APS; Functional Assessment of Cancer Therapy-Breast subscale; chronic sensory and motor neurotoxicity and adverse events. RESULTS: The overall incidence of T-APS across all cycles of chemotherapy in the etoricoxib group was 57.1%, while that in the control group was 91.5% (P < 0.001). The incidences of severe T-APS were 11.4% and 54.9% for the etoricoxib and control groups, respectively (P < 0.001). The mean Functional Assessment of Cancer Therapy-Breast subscale score of the etoricoxib group (103.79-107.24) was significantly higher than that of the control group (93.88-96.71) (P = 0.001 at cycle 1 and P < 0.001 at cycles 2-4). After four cycles of docetaxel chemotherapy, the etoricoxib group demonstrated a significantly higher mean Functional Assessment of Cancer Treatment Neurotoxicity subscale score than the control group (38.46, 95% CI: 37.63-39.29; 34.59, 95% CI: 33.73-35.45, respectively; P < 0.001). Electromyography showed that most peripheral sensory nerves in the etoricoxib group had significantly improved action potential amplitudes and conduction velocities compared with those in the control group. CONCLUSION: Prophylactic use of etoricoxib could significantly reduce the incidence and severity of docetaxel-induced acute pain syndrome and potentially decrease docetaxel-induced peripheral neuropathy. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04565600.
引用
- Zhang J, Gao HF, Yang C, et al. Prevention of taxane-associated acute pain syndrome with etoricoxib for patients with breast cancer: A phase II randomised trial. Eur J Cancer. 2022. PMID: 35724467. doi:10.1016/j.ejca.2022.05.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。